HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma

American Journal of Clinical Pathology

Volumn 113, Issue 6, 2000, Pages 852-859

  Hoang, M P ^a   Sahin, A A ^a   Ordonez N G ^a   Sneige, N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast carcinoma; C erbB 2; Fluorescence in situ hybridization; Gene amplification; HER 2 neu; HercepTest; Herceptin; Immunohistochemistry; Interobserver reproducibility

Indexed keywords

ARTICLE; BREAST CARCINOMA; CANCER INVASION; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; OBSERVER VARIATION; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPRODUCIBILITY; SCORING SYSTEM; SCREENING TEST;

ADENOCARCINOMA; ADULT; AGED; BREAST NEOPLASMS; EVALUATION STUDIES; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; OBSERVER VARIATION; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS;

EID: 0034515613     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/VACP-VLQA-G9DX-VUDF     Document Type: Article

References (22)

1. Treatment of early-stage breast cancer
2. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
3. Studies of the HEg-2/neu proto-oncogene in human breast and ovarian cancer
4. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node negative breast carcinomas
5. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer
6. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32
7. The neu oncogene encodes an epidermal growth factor receptor-related protein
8. The role of the epidermal growth factor receptor and the c-erbB-2 protein in breast cancer
9. HER-2/neu monoclonal antibody plus cisplatin in patients with HER-2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
10. HER-2 breast assay, linked to Herceptin wins FDA's okay
11. How should HER2 status be determined?
12. Comparison of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) for the evaluation of HER-2/neu
13. High correlation between ERBB2 amplification detected by FISH and gene overexpression detected by immuno-histochemistry in breast cancers
14. Fluorescent in situ hybridization (FISH) vs immunohistochemistry (IHC) for determination of HER-2/neu status in breast cancer
15. In situ hybridization as a tool to study numerical chromosome aberrations in solid bladder tumors
16. The measurement of observer agreement for categorical data
17. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization
18. Heterodimerization and functional interaction between EGF receptor family members: A new signaling paradigm with implications for breast cancer research
19. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in-situ hybridization
20. Initial report of the SWOG biological correlative study of C-ERB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen (T) alone
21. Addition of Herceptin (humanized anti-HER2 antibody) to first-line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2 +/MBC) markedly increases anticancer activity: A randomized, multinational controlled phase III trial